Lexaria Bioscience prices public offering of 2.1M units at $0.95/unit for $2.0M gross proceeds

Lexaria Bioscience Corp.

2,106,000 units priced at $0.95 each, each unit comprising one share of common stock and one warrant.
Gross proceeds expected ~$2.0M before fees; warrants exercisable at $0.95 for 5 years.
Offering expected to close May 11, 2023; Maxim Group LLC sole placement agent.
Registration statement on Form S-1 (File No. 333-271096) declared effective May 8, 2023.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lexaria Bioscience Corp. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-05-08).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Effective: 2023-05-08

Exact text from the filing

On May 8, 2023, Lexaria Bioscience Corp. (the “Company”) entered into a placement agency agreement dated as of May 8, 2023 (the “PAA”) with Maxim Group LLC (the “Placement Agent”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lexaria Bioscience Corp. entered into Security Purchase Agreement with certain institutional investors valued at up to an aggregate of $247,000 of Units (effective 2023-05-08).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: up to an aggregate of $247,000 of Units
Effective: 2023-05-08

Exact text from the filing

On May 8, 2023, the Company also entered into a security purchase agreement (the “Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”) in connection with the Offering.

View on SEC.gov

Browse all material agreements →

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-23-000800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.